Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Change in Accured Expenses: 2023-2025

Historic Change in Accured Expenses for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $1.2 million.

  • Tonix Pharmaceuticals Holding's Change in Accured Expenses rose 163.16% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 21.07%. This contributed to the annual value of $1.2 million for FY2024, which is 33.37% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Change in Accured Expenses stood at $1.2 million, which was down 62.83% from $3.4 million recorded in Q2 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's Change in Accured Expenses peaked at $4.4 million during Q4 2023, and registered a low of -$3.0 million during Q1 2023.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Change in Accured Expenses averaged around $421,727, with its median value being $913,000 (2024).
  • Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's Change in Accured Expenses showed a top increase of 268.35% in 2025 and a maximum decrease of 68.96% in 2025.
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Change in Accured Expenses stood at $4.4 million in 2023, then tumbled by 65.02% to $1.5 million in 2024, then surged by 163.16% to $1.2 million in 2025.
  • Its Change in Accured Expenses was $1.2 million in Q3 2025, compared to $3.4 million in Q2 2025 and -$3.0 million in Q1 2025.